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Abstract: A prospective multicentric study was carried out in patients having metal-on-
metal METASUL components (Sulzer Medica, Winterthur, Switzerland) in order to check the
following null hypotheses:
H1: The concentration of Co, Cr, Ni, and Mb in blood and urine is not modified by the implant
of a hip prosthesis with METASUL components at 6 months.
H2: The incidence of markers of chromosomal damage [sister chromatid exchanges (SCEs)
and micronuclei (Mni)] in lymphocytes is not modified by the implant of METASUL compo-
nents at 6 months.
H3: The concentrations of Co, Cr, Ni, and Mb in blood and urine did not correlate with the
incidence of the markers of chromosomal damage.
The measurements showed a 2-fold increase of Co in blood, a 10-fold increase of Co in urine,
a 1.5-fold increase of Cr in the blood, and a 3-fold increase of Cr in the urine at a follow-up
of 6 months from the operation; there was also a significant increase in the Ni blood
concentration at the 7 day checkup. The study cohort did not show any modification in the
frequency of markers of chromosomal damage in the peripheral lymphocytes at any of the
observation times. The amount of the SCEs and Mni recorded at all the observation times did
not correlate with each other or with any of the ion levels measured in the blood and in the
urine. © 2003 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 67B: 750–757, 2003
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INTRODUCTION
The degradation and wear of the components used in ortho-
pedic prosthetic surgery result in the release of metal ions that
both accumulate in the tissues surrounding the implant and
enter the bloodstream. Some of these ions were found to have
the ability to induce chromosomal damage (genotoxicity or
mutagenicity) and/or to induce the development of cancer
(carcinogenicity). In the CoCr alloys, Cr and Ni have estab-
lished carcinogenic compounds, and Co is classified as a
possible carcinogen itself.1
Evidence of these effects in experimental studies in vitro and
in vivo raised a question about the possible increased risk of
local and remote neoplasm in patients who underwent joint
replacement. Several authors compared the incidence of neo-
plasm in the general population against that in patients with
joint prostheses. While the risk of incidence of local neo-
plasm in the site of the implant was found to be negligible,
these studies were unable to give an unequivocal answer
regarding the incidence of remote neoplasm. Gillespie et al.
first reported a slight increase of tumors of the lymphatic and
hemopoietic systems in patients with hip prosthesis.2 This
result was confirmed by Visuri and Koskenvuo in subjects
with metal-on-metal McKee–Farrar hip prostheses.3 Two fur-
ther studies, comparing the overall cancer risk in operated-on
cohorts with rates derived from national data in Sweden could
not support the hypothesis of an increased risk in patients
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with hip replacement.4,5 In a later study, Visuri et al. com-
pared a cohort of patients with McKee–Farrar prostheses with
patients with metal-on-polyethylene articulation: Both co-
horts showed a lower incidence of cancer with respect to the
general population, but the risk was lower in the metal–
polyethylene group than in the metal–metal group.1 The
release of metal particles and ions from the McKee–Farrar
prostheses was hypothesized to be the cause of the increased
risk of lymphoma and leukemia.6,7
The interest about the McKee–Farrar study was renewed
since, metal-on-metal articulation from cobalt–chromium–
molybdenum alloy was reintroduced into hip arthroplasty as
an alternative to polyethylene and ceramic components in
1988.8,9 The newer design, material, and fabrication technol-
ogy of this second generation of metal–metal components are
the basis of their good clinical results at medium-term fol-
low-up reported in literature.10–12 On the other hand, the
increased concentration of cobalt and chromium in the body
fluids found in patients who underwent the implant of such
metal-on-metal components led to some concern about the
possible long-term carcinogenic effect of the exposure to
such high metal concentrations.13
A prospective multicentric study was carried out in pa-
tients having metal-on-metal METASUL components (Sulzer
Medica, Winterthur, Switzerland) with the aim of rejecting
the following null hypotheses:
H1: The concentration of cobalt (Co), chromium (Cr),
nickel (Ni), and molybdenum (Mb) in blood and urine is not
modified by the implant of a hip prosthesis with METASUL
components at 6 months.
H2: The incidence of markers of chromosomal damage in
lymphocytes is not modified by the implant of METASUL
components at 6 months.
H3: The concentrations of Co, Cr, Ni, and Mb in blood and
urine did not correlate with the incidence of the markers of
chromosomal damage.
The sister chromatid exchanges (SCEs) and the micronu-
clei (Mni) were used as markers of chromosomal damage for
the determination of the genotoxicity.
PATIENTS AND METHODS
Patient Enrollment
Between 1999 and 2001 thirty patients were consecutively
chosen from among those selected for the implant of an
uncemented hip prosthesis with METASUL components
(Figure 1). The patients fit the following inclusion criteria:
● Age below 65 years
● Diagnosis of primary osteoarthritis, congenital hip dyspla-
sia, or avascular necrosis
● Smoking habit below five cigarettes/day
● Absence of history of occupational exposure to Cr, Co, and
Ni dusts
● Absence of history of diseases able to induce DNA damage
● Absence of known systemic diseases
● Absence of history of pharmacological treatments able to
induce an increase in the amount of the markers of geno-
toxicity (cytostatic, antianxiety, antipsychotic, and antima-
niacal drugs, estrogens, anticonvulsants)14
● Acceptance of the study protocol.
The study cohort was formed by 10 males and 20 females;
the mean age was 52 years (range 34–64 years).
The implanted components are reported in Table I. Poste-
rior-lateral surgical approach was used for all implants. The
postoperative rehabilitation protocol was the same in all
cases: two days of bed rest and subsequent walking recovery;
weight bearing with two crutches for the first month, one
crutch for the second month, full weight bearing after the
2-months checkup.
Blood and Urine Sampling
Blood and urine samples were taken previous to surgery, at 7
days and at 2 and 6 months after surgery; three blood samples
Figure 1. The ARMOR acetabular component with METASUL insert
(Sulzer Medica, Winterthur, Switzerland).
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(5 ml) and one urine sample were taken at each observation
time.
Peripheral blood samples were taken by using a venflon
canula inserted into a vein in the forearm. The first blood
sample was placed in a Hemogard Vacutainer plastic con-
tainer with lithium–heparin as anticoagulant (Becton Dick-
inson Vacutainer Systems, Meylan), and was used for the
analysis of the chromosomal damage; the second and third
blood samples were placed in a Hemogard Vacutainer
plastic container with K2-EDTA as anticoagulant, and were
used to measure the ion level in the whole blood. This
sequence was aimed at reducing the metal contamination
in the samples for the ion measurement by washing out
metal residuals from the needle with the blood in the first
sample.
Ion-Level Measurement
The concentrations of cobalt, chromium, nickel, and molyb-
denum were measured in whole blood and urine by furnace
Zeeman atomic absorption spectrophotometry (Perkin Elmer
4100 ZL). The blood samples were analyzed after dilution 1:1
with Triton X-100 0.1% solution and subsequent direct anal-
ysis, and the urine samples were directly analyzed without
dilution. The validation of the measurements was performed
by comparison with certified standards (NYCOMED Se-
ronorm Trace Elements). The detection limits of the spectro-
photometry were: 0.10 g/l for Cr in blood and for Cr and Co
in urine, 0.20 g/l for Co and Ni in blood and Ni in urine, and
0.50 g/l for Mb in blood and urine.
Sister Chromatid Exchange and Micronucleus Tests
For the analysis of sister chromatid exchange (SCE) blood
was cultured, within 24 h of drawing, in medium RPMI 1640
(Sigma Chimica, Milano, Italy) supplemented with 30% fetal
bovine serum (FBS, Sigma Chimica) and 10 g ml1 phy-
tohemagglutinin (PHA, Sigma Chimica), 100 U ml1 peni-
cillin, and 50 U ml1 streptomycin. The cultures were incu-
bated for 72 h at 37 °C: after 24-h culture, 5 g ml1
bromodeoxyuridine (Sigma Chimica) was added, and 1 h
before cell harvesting 0.25 g ml1 colchicine (Colcemid,
Sigma Chimica) was added to each culture to arrest mitosis.
After hypotonic treatment (KCl 0.56%) and cell fixing by
methanol and acetic acid (3:1), preparations were stained
with 1.5% Giemsa and microscopically examined. SCEs were
scored in 40 metaphase cells from each culture where the
most striking feature of metaphase is that all the chromo-
somes become aligned with their centromeres in a single
transverse plane. In first-division cells (M1) all the chromo-
somes were stained dark, whereas in third or subsequent
divisions (M3) they were lightly stained. In second-division
cells (M2) all the chromosomes showed differential stain-
ing.15,16
The same lymphocyte technique employed for SCEs was
used for the micronucleus (Mni) test.17). After 44 h of incu-
bation Cytochalasin B (Cyt-B, Sigma Chimica) was added at
a final concentration of 6 g ml1and the cells were cultured
for 72 h at 37 °C. Cyt-B, inhibited cytokinesis, and binucle-
ated cells are accumulated in the first division cycle. After
hypotonic treatment (KCl 0.56% and NaCl 0.9% 1:1) at room
temperature the cells were fixed in methanol and acetic acid
(3:1) and stained in Giemsa (5%). The frequency of Mni was
estimated by blind scoring of 1000 binucleate cells at a 
1000 magnification. Briefly, micronuclei were scored in cy-
tokinesis-blocked cells easily recognizable given their binu-
cleate appearance indicating they must be dividing cells hav-
ing completed nuclear but not cytoplasmic division.
Statistical Analysis
All data were recorded in a custom-made database and ana-
lyzed with a software program (SAS ver. 8.1, SAS Institute
Inc., Cary, NC). Statistical significance was stated at 5% for
all the tests performed (  0.05).
In order to check null hypotheses H1 and H2 the ion level
in blood and urine and the amount of SCEs and Mni mea-
sured at each postoperative observation time were compared
with the preoperative values by paired t test (normal distri-
bution of the differences) or by the sign rank test (nonnormal
distribution of the differences).
The analysis of variance (ANOVA) for repeated measures
was used to analyze the trend of the measured parameters
during the observation period. The correlation between the
ion levels and the markers of chromosomal damage (null
hypothesis H3) was studied by Pearson correlation coefficient
TABLE I. Details of the Components Implanted. The Artek Cup has an Internal Diameter of 38 mm, and a few All the Other
Acetabular Components Have an Internal Diameter of 28 mm. Because Only Artek Cups are Present in the Study Cohort, the
Diameter of the Head Was Not Considered as a Variable for the Statistical Analyses
Stem Composition
No.
Implanted Cup Composition (Metal Back)
No.
Implanted
Alloclassic Protasul-100 24 Alloclassic Protasul-Ti 4
Zweymu¨ller (Ti-6Al-Nb) Zweymu¨ller (Ti)
CLS Protasul-100 (Ti-6Al-Nb) 4 Armor Protasul-Ti (Ti) 20
Stelcor Protasul-100 (Ti-6Al-Nb) 2 Artek Protasul-100 (Ti-6Al-Nb) 4
Marburg Protasul-Ti (Ti) 2
752 MASSE` ET AL.
analysis. In order to check the congruency of the sample size,
the  error and the power of each test performed (1 ) were
calculated.
RESULTS
The overall results of the assays are reported in Tables II and
III.
Ion-Level Measurement
Cobalt. There was an increase in the Co blood levels
during the observation period: The difference between the
preoperative level (median 0.96 g/l ) and the 6-month level
(median 2.05 g/l) was statistically significant (p  0.001).
As to the urinary excretion of Co the concentration recorded
preoperatively (median 1.04 g/l) was significantly lower
than that recorded at 7 days (median 1.47 g/l; p  0.001),
TABLE II. Results of the Ion-Level Measurement. The t Test or the Sign-Rank Test were Used Alternatively, Depending on the
Normality of the Results, To Compare the Preoperative Results with Those at the Different Postoperative Observation Times. The
Ion Concentration Is Expressed in g/l
Variable
Pre-op Mean
[DS] Median
P (Normality)
7 Days
Mean [DS]
Median
P (Normality)
P (t test)
P (Sign-Rank Test)
2 Months
Mean [DS]
Median
P (Normality)
P (t test)
P (Sign-Rank Test)
6 Months
Mean [DS]
Median
P (Normality)
P (t test)
P (Sign-Rank Test)
Co (blood) 1.23 [1.03] 1.43 [1.52] 2.13 [2.72] 2.32 [1.45]
0.96 1.25 1.45 2.05
0.001 0.001 0.001 0.02
0.47 0.12 0.001
0.49 0.29 0.001
Co (urine) 1.13 [0.88] 2.32 [1.96] 6.41 [7.35] 10.07 [13.83]
1.04 1.47 3.80 5.20
0.01 0.01 0.01 0.01
0.01 0.001 0.01
0.001 0.001 0.001
Cr (blood) 1.14 [1.03] 1.57 [1.28] 1.34 [0.73] 1.70 [1.04]
0.75 1.40 1.32 1.38
0.001 0.001 0.55 0.01
0.16 0.49 0.03
0.05 0.22 0.03
Cr (urine) 0.86 [1.88] 2.62 [4.54] 2.10 [1.18] 2.81 [2.98]
0.41 1.19 1.89 1.65
0.001 0.001 0.27 0.001
0.05 0.02 0.001
0.001 0.001 0.001
Mo (blood) 1.05 [0.87] 1.09 [1.03] 1.13 [0.89] 1.71 [1.82]
0.80 0.60 0.80 1.15
0.001 0.001 0.001 0.001
0.94 0.78 0.14
0.80 0.83 0.42
Mo (urine) 5.91 [4.94] 4.38 [4.84] 9.58 [9.59] 10.49 [9.68]
4.25 2.50 7.00 5.90
0.01 0.001 0.001 0.001
0.04 0.11 0.07
0.01 0.22 0.19
Ni (blood) 2.58 [4.09] 2.01 [4.51] 3.71 [7.91] 3.00 [4.83]
1.40 1.20 1.10 1.60
0.001 0001 0.001 0.001
0.09 0.58 0.73
0.17 0.67 0.53
Ni (urine) 3.41 [6.89] 3.88 [3.63] 2.41 [3.06] 2.38 [2.10]
1.36 3.28 1.75 1.67
0.001 0.001 0.001 0.001
0.89 0.69 0.45
0.05 0.33 0.37
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at 2 months (median 3.80 g/l; p  0.001) and at 6 months
(median 5.20 g/l; p  0.001) (Figure 2, Table II).
Chromium. There was a significant increase in the
amount of blood Cr concentration at 7 days (median 1.40
g/l; p  0.05) and at 6 months (median 1.38; p  0.03)
compared to the preoperative level (median 0.75 g/l). In
urine samples, the amount of Cr was preoperatively signifi-
cantly lower than that recorded at all the observation times
(pre-op: median 0.41 g/l; 7 days: median 1.19 g/l, p 
0.001; 2 months: median 1.89, p  0.001; 6 months: median
1.65 g/l, p  0.001) (Figure 2, Table II).
Molybdenum. The blood level of Mb did not undergo any
significant modification during the observation period; the
same was found for the urinary levels with the exception of a
significant decrease at 7 days (preop: median 4.25 g/l; 7
days: median 2.50 g/l, p  0.04) (Figure 2, Table II).
Nickel. The blood levels of Ni recorded postoperatively
did not differ significantly from the preoperative level,
whereas urine levels showed a significant increase of Ni at the
7day measurement (pre-op: median 1.36 g/l; 7 days: median
3.28, p  0.05) (Figure 2, Table II).
Sister Chromatid Exchange and Micronucleus Tests
The amount of SCEs slightly decreased during the observa-
tion period from a preoperative mean of 6.01 to 5.43 at 6
months; however, the statistical analysis did not reveal any
TABLE III. Results of the SCEs and Mni Tests. The Statistic Analysis Was Performed as for Table II
Variable
Pre-op
Mean [DS]
Median
P (normality)
7 Days
Mean [DS]
Median
P (Normality)
P (t Test)
P (Sign-Rank Test)
2 Months
Mean [DS]
Median
P (Normality)
P (t Test)
P (Sign-Rank Test)
6 Months
Mean [DS]
Median
P (Normality)
P (t Test)
P (Sign-Rank Test)
Mni 6.12 [3.20] 6.59 [3.28] 5.26 [3.10] 5.72 [3.55]
5.50 6.00 5.00 5.00
0.52 0.15 0.11 0.01
0.49 0.70 0.54
0.39 0.65 0.34
SCEs 6.75 [4.06] 6.28 [1.75] 5.80 [1.56] 5.60 [1.22]
6.01 5.80 5.60 5.43
0.01 0.13 0.47 0.28
0.76 0.29 0.20
0.90 0.64 0.40
Figure 2. Median concentrations of Co, Cr, Mb, and Ni in blood and urine.
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significant difference between pre-operative values and those
recorded at all the postoperative observation times (Table
III). The power of the test performed was 94.1%, assuming a
differential threshold of 2 SCEs between the preoperative and
the 6-months values (99.7% with a threshold of 3 SCEs).
The Mni did not show any significant difference between
the values recorded at the different observation times (Table
III). The power of the test was 75.5%, assuming a differential
threshold of 2 Mni between the preoperative and the
6-months values (96.2% with a threshold of 3 Mni).
Correlation between the Ion Levels and the
Indicators of Genotoxicity
The amount of the SCEs and Mni recorded at all the obser-
vation times did not correlate with each other nor with any of
the ion levels measured in the blood and in the urine.
DISCUSSION
The ions that were measured (Co, Cr, Mo, Ni) are all defined
as essential metals for the human organism: This means that
they are, at a given amount, an essential part of at least one
enzyme and that there is a mechanism of homeostasis to
avoid their accumulation. This mechanism is represented by
the transportation system from the local tissues to the blood
and by the subsequent elimination through the urine; this
clearance mechanism is very effective for Co, Mo and Ni,
which are almost completely excreted within 24–48 hours.18
As for the Cr, it has been shown that the urinary excretion
is not fully effective and that it tends to accumulate in the
tissues and in red blood cells. In order to measure the Cr in
the red blood cells as well, the present study was performed
on whole blood rather than on serum.
The study of the ion concentration in blood and urine
showed that the implantation of metal-on-metal prostheses
determines a significant increase in the concentration in the
blood and, more significantly, in the urine, of the main
components of the implanted metal alloys, Co and Cr. Mea-
surements showed a 2-fold increase of Co in blood, a 10-fold
increase of Co in urine, a 1.5-fold increase of Cr in blood and
a 3-fold increase of Cr in urine at a follow-up of 6 months
from the operation; there was also a significant increase in the
Ni blood concentration at the 7-day checkup. These findings
are in agreement with previous reports and lead to the rejec-
tion of the null hypothesis H1.
Gleizes et al. reported a 10-fold concentration of Co con-
centration in serum at a mean follow-up of 12.9 months in 41
patients with metal-on-metal articulation.19 Jacobs reported a
3-fold increase of Co concentration in serum, a 9-fold in-
crease of Cr concentration in serum, and a 35-fold increase of
Cr concentration in urine in eight patients implanted with
McKee–Farrar prostheses in comparison with control sub-
jects at a follow-up of more than 20 years.7
Cobalt in serum does not necessarily originate from the
metal-on-metal articulation alone: Kreibich reported a 2-fold
increase in Co serum concentration in 14 patients with aseptic
loosening of porous-coated anatomic (PCA, Howmedica In-
ternational) hip replacement with metal-on-polyethylene cou-
pling against a group of patients with the same stable com-
ponents.20 Brien et al. found a significant increase of Co and
Cr in the synovial fluids of loose Co–Cr cemented stems with
metal-on-polyethylene coupling at revision against stable
components.21
The clinical interest in the release of metal from CoCr
components derives from the evidence that a significant pro-
portion of the Cr released as ions in patients with total hip
replacements is Cr6 rather than the dietary form Cr3.22 The
Cr6 can be reduced to Cr3 inside the cells by biological
reductants in reactions that give rise to Cr4 and Cr5 un-
stable intermediates; the ability of such intermediates to in-
duce DNA damage determines the carcinogenic ability of
Cr6. Wu described an increase in SCEs in peripheral lym-
phocytes in workers exposed to chromium compounds.23
Other epidemiological studies have shown a strong associa-
tion of occupational exposure to chromate particles and the
incidence of nasal and lung cancer.24
To date, no consensus has been reached on possible car-
cinogenicity of cobalt ions, while their mutagenic properties
have been proven in in vitro experimental models.25
Nickel was found to be both genotoxic in vitro and carci-
nogenetic in vivo (lung and ethmoidal bone) with a consid-
erable latency after the exposure;26 no description was found
in the literature regarding the genotoxic or carcinogenetic
effects of molybdenum.
Despite the increased concentration of Co and Cr, the
present study cohort did not show any modification in the
frequency of sister chromatid exchanges and micronuclei in
the peripheral lymphocytes at any of the observation times.
The sister chromatid exchanges (SCEs) and the micronuclei
(Mni) were used as endpoints for the determination of the
genotoxicity because of their sensitivity to the actions of
carcinogenic and mutagenic substances.23,27 The Mni are
small extranuclear bodies that are formed in mitosis from
acentric chromosomal fragments or chromosomes that are not
included in either daughter nucleus; the SCEs result from the
interchange of DNA replication products at apparently iden-
tical loci of the sister chromatid of a chromosome in response
to a damaged DNA template. Even if a direct association
between their frequency and the risk of cancer is not de-
scribed, they are thought to reflect genomic instability.27
The study of the power of the tests of genotoxicity showed
that the sample size was adequate; therefore the null hypoth-
esis H2 is accepted: The incidence of markers of chromo-
somal damage in lymphocytes was not modified by the im-
plant of METASUL components at 6 months.
The absence of any correlation among the SCEs, the Mni
and the ion concentration in the blood and urine (null hy-
pothesis H3) can be explained by the fact that the measured
concentrations of Co, Cr, and Ni did not exceed in any case
the threshold for exposed workers defined as nontoxic by
several authors.25,28
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In summary, the present study has shown that the implant
of prostheses with METASUL components determines an
increase in the concentrations of mainly Co and Cr in blood
and urine, but that this increase has no genotoxic effects on
the peripheral lymphocytes in the selected group at a fol-
low-up of 6 months.
In contrast to these findings, other studies have shown an
increase of chromosomal changes in patients who underwent
hip replacement. For example, Stea and co-workers found a
significantly higher number of SCEs in peripheral lympho-
cytes in patients with prostheses with metal-on-polyethylene
gliding coupling made mainly by Ti–Al–Va alloy or ce-
mented than in a control group of untreated patients.14 Re-
cently, Doherty and co-workers described a significant in-
crease of genetic changes in blood lymphocytes at revision
arthroplasty. Their study has shown a correlation between the
type of chromosomal change and the metal composition of
the implanted prosthesis.29 The difference between these
finding and the results of the present study can be probably
explained by the differences in the study design (prospective
vs. case control), in the composition of the implanted com-
ponents (cemented or uncemented Ti–Al–Va alloy), in the
criteria of enrollment of the patients, and in the length of the
follow-up; furthermore, Doherty used different endpoints to
determine the chromosomal damage (aneuploidy and chro-
mosome translocations).
The criteria of enrollment of the patients adopted in this
study were aimed at obtaining a homogeneous group of
patients with no history of exposure to other metal sources, to
factors able to modify the amount of indicators of genotoxic
damage of the lymphocytes, without known systemic dis-
eases and therefore with normal mechanisms of clearance of
the metal ions. It is therefore not possible to exclude that the
implanting of metal-on-metal components could determine an
increase at pathological ion concentrations in patients ex-
posed to other metal sources. Furthermore, a deficiency in the
mechanisms of ion clearance, as occurs in chronic renal
insufficiency, can determine by itself a pathologic increase of
the concentrations of the metals released.30 Therefore, in the
presence of such conditions, the implanting of prostheses
with metal-on-metal gliding contact should perhaps be
avoided.
The length of the follow-up is another critical point: Some
metals are reported to rise to their highest concentrations in
the body fluids shortly after an operation, due to a possible
“running in” effect.7 This assumption should be not true for
chromium, which tends to partially accumulate in the tissues.
Furthermore, the cementless metal-on-metal prostheses are
particularly implanted in young adults. Hence, the long life
expectancy of those patients corresponds to a long-term ex-
posure to increased metal concentrations. Even if in the
literature we could not find any report correlating the length
of the follow-up and the amount of genetic changes or the
development of neoplastic diseases, this aspect makes it man-
datory to further investigate the long-term risk after joint
implantation.3
The authors would like to thank Mr. Paolo Spinelli and Mr.
Valerio Bergo for their fundamental help in the atomic absorption
spectrophotometry.
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